Stock MNMD MIND MEDICINE (MINDMED) INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Mind Medicine (MindMed) Inc.

Equities

MNMD

CA60255C8850

Real-time Estimate Cboe BZX
Other stock markets
 14:24:26 2024-06-26 EDT 		5-day change 1st Jan Change
7.255 USD +2.62% Intraday chart for Mind Medicine (MindMed) Inc. -2.07% +93.99%
06-24 Mind Medicine Inc.(NasdaqGS:MNMD) added to S&P Pharmaceuticals Select Industry Index CI
06-20 Mind Medicine Inc Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
MindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
AQ
MindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
BU
MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)
BU
MindMed ICPR 2024: Rapid and Durable Response to a Single Dose of MM120 (Lysergide) in Generalized Anxiety Disorder: A Dose-Optimization Study
PU
MindMed to Participate in June Conferences
BU
Mind Medicine (MindMed) Inc. - New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting Show Growing Burden and Impact of Generalized Anxiety Disorder in the US
AQ
MindMed to Participate at May Investor Conferences
BU
New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US
BU
MindMed Reports First Quarter 2024 Financial Results and Business Updates
BU
MindMed ISPOR 2024: Work Productivity and Activity Impairment Associated with Generalized Anxiety Disorder among Adults in the United States
PU
MindMed ISPOR 2024: Health-related Quality of Life Associated with Generalized Anxiety Disorder among Adults in the United States
PU
MindMed ISPOR 2024: Health Care Resource Use Associated with Generalized Anxiety Disorder among Adults in the United States
PU
MindMed APA 2024: Screening Adults in the US General Population to Detect Cases of Undiagnosed Generalized Anxiety Disorder
PU
MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York
BU
MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update
BU
MindMed to Present at Upcoming May Medical Conferences
BU
MindMed to Present at Upcoming April Medical Conferences
BU
MindMed Announces Voluntary Delisting from Cboe Canada
BU
MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference
BU
Mind Medicine MindMed : Investor Presentation - MM120 for Generalized Anxiety Disorder Conference Call and Webcast
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MNMD Stock
  4. News Mind Medicine (MindMed) Inc.
  5. Press Releases